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Summary 
Monoclonal antibodies (mAbs) specific  for the murine p55 and p75 tumor necrosis factor (TNF) 
receptors were produced after immunization of Armenian hamsters with the purified soluble 
extracellular domains of each receptor protein.  Four p55- (55R) and five p75 (TR75)-reactive 
mAbs immunoprecipitated the appropriate receptor from the surface of L929 cells. None of the 
mAbs cross-reacted  with the other TNF receptor form. The mAbs were functionally characterized 
by their ability to inhibit ligand binding and influence TNF-dependent L cell cytolytic activity 
or proliferation of the murine cytolytic T cell clone CT6. One p55-specific  mAb, 55R-593, displayed 
agonist activity, while two other p55-specific mAbs (55R-170 and -176) were found to be TNF 
antagonists.  The fourth mAb (55R-286)  had no functional  effects on cells. Several antibodies 
specific for the p75 TNF receptor partially inhibited  recombinant murine TNF-c~-dependent 
cytolytic activity (60%). Blocking mAbs specific  for p75 but not anti-p55 inhibited TNF-mediated 
proliferation of CT6 T cells. When used in vivo, p55- but not p75-specific mAbs protected mice 
from lethal endotoxin shock and blocked development of a protective response against Listeria 
monocytogenes infection. In contrast,  both p55 and p75 mAbs individually blocked development 
of skin necrosis in mice treated with murine TNF-c~. These data thus demonstrate the utility 
of the two families of murine TNF receptor-specific mAbs and identify a novel function of the 
p75 TNF receptor in vivo. 
T 
NF, originally identified by its ability to effect hemor- 
rhagic necrosis of specific tumors (1), is now known to 
play a major role in promoting immunologic, inflammatory, 
and pathobiologic reactions (2). TNF's pleiotropic activities 
are induced after binding of the homotrimeric ligand to ei- 
ther of two distinct  cell surface receptors of 55 and 75 kD 
that are independently expressed on a variety of different cell 
types (3, 4). The cDNAs and genes for the murine and human 
p55 and p75 TNF receptors have been cloned and expressed 
and the proteins they encode characterized (5-9).  Although 
the extracellular domains of the two TNF receptors are 28% 
identical, no homology has been found between the intracel- 
lular domains of the two proteins (10). This observation sug- 
gests that the two receptors may be responsible for inducing 
distinct  cellular responses. The murine p55 TNF receptor 
binds both murine and human TNF-cr  In contrast, the mu- 
fine p75 receptor binds only its homologous murine ligand 
and not the human homologue (8,  9). 
Work is ongoing to define the functional roles of the p55 
and p75 TNF receptors on various cell types. The p55 receptor 
is now known to be important for inducing in cells a wide 
variety of functions such as cytolytic activity (11, 12), an- 
tiviral activity (13), expression of manganous superoxide dis- 
mutase (14) and intercellular adhesion molecule (ICAM)  1 1 
(15, 16), IL-6 mRNA accumulation (17, 18), and NF-KB in- 
duction (12, 15,  19,  20). Recent experiments  using p55- 
deficient mice have demonstrated that the p55 TNF receptor 
plays a physiologically important role in promoting lethal 
shock induced by LPS and galactosamine and in effecting an- 
timicrobial responses to Listeria monocytogenes (21, 22). In con- 
trast, little information is available concerning the biologic 
responses mediated by the p75 TNF receptor. In vitro ex- 
periments have suggested that p75 enhances p55-induced bio- 
logic responses by facilitating binding of TNF to p55 (23, 
24). In addition,  p75 induces proliferative responses in cer- 
tain cells of hematopoietic  origin and enhances expression 
of certain adhesion molecules such as ICAM-1 (11, 14, 25-27). 
1Abbreviations used in  this paper: HuTNF, MuTNF, and  MulFN, 
recombinant  human  and mufine  TNF-~ and IFN-% respectively;  ICAM, 
intracellular adhesion molecule. 
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against the human TNF receptors, no mAbs are currently 
available that are reactive with the murine TNF receptor pro- 
teins. Herein, we report the production and characterization 
of hamster mAbs specific for the murine p55 and p75 TNF 
receptors. The functional activities of these antibodies are 
demonstrated in well-defined in vitro systems and subsequently 
by use of in vivo murine models of lethal shock and anti- 
Listeria responses. Finally, using an in vivo model of TNF- 
induced skin necrosis in mice, we identify a novel physio- 
logic role of p75. 
Materials and Methods 
Animals.  C57BI/6J,  CBA/J, BALB/cByJ, and C3H/HeJ fe- 
male mice 6-12 wk of age were purchased from The Jackson Labo- 
ratory (Bar Harbor,  ME) and maintained in microisolator cages. 
Male Armenian hamsters were obtained from Cytogen Research 
and Development, Inc. (Cambridge, MA). Goats were purchased 
through and maintained at the Washington University School of 
Medicine Tyson Research Center. 
Reagents and Materials.  Media, supplements, and buffers used 
in these experiments were purchased or prepared as previously de- 
scribed (28, 29) and contained <0.005 endotoxin units/ml as de- 
termined by the Limulus amebocyte lysate assay (BioWhittaker Inc., 
Walkersville, MD). Purified recombinant murine TNF-c~ (MuTNF) 
(1.2  x  107 U/mg), recombinant human TNF-cr (HuTNF) (5.6  x 
107 U/mg) and recombinant murine IFN-3' (MulFN) (4.7  x  106 
U/mg) were produced by Genentech, Inc. (South San Francisco, 
CA). MuTNF was radiolabeted to a specific  activity of 10.8/ICi//xg 
by use of NanSI (ICN Biomedicals, Inc., Irvine, CA) and Iodo- 
beads (Pierce Chemical  Co.,  Rockford,  IL)  according  to  the 
manufacturers' directions. Iodinated HuTNF (800 Ci/mmol) was 
purchased from Amersham (Arlington Heights, l'L). Purified soluble 
extracellular domains of the p55 and p75 murine TNF receptors 
were prepared as described (8, 30) and radioiodinated by use of the 
Bolton-Hunter reagent (ICN Biomedicals, Inc.) according to the 
manufacturer's directions to a specific  activity of  3.2 and 9.2 #Ci//zg, 
respectively. LPS (Escherichia coli strain 0111:B4) and n-galactosamine 
were obtained from Sigma Chemical Co.  (St. Louis, MO). 
Antibodies.  The following previously described and character- 
ized hamster mAbs were used in this study: TN3-19.12 (anti-routine 
TNF-c~) (29), JAMA-147 (anti-murine type I IL-1 receptor) (31), 
and H22 (anti-murine IFN-qr) (28); L2-3D9 (29) and 6C8 (32) are 
control hamster mAbs not reactive with naturally occurring mu- 
fine proteins. Polyvalent rabbit p55- and p75-specific  antisera were 
produced as previously described (11). Anti-hamster IgG was pro- 
duced by immunization  of goats with purified Armenian hamster 
IgG. Hamster IgG-specific antibodies were purified from immune 
sera purified by affinity chromatography by use of agarose-bound 
Armenian hamster IgG. Purified antibodies were biotinylated by 
use of the Enzotin reagent (Enzo Biochemical, Inc., New York) 
according to the manufacturer's instructions. 
Production of  Anti-TNF Receptor Antibodies.  Hamster mAbs were 
generated from Armenian hamsters as previously  described (28, 29). 
Animals were immunized intraperitoneally with the soluble  purified 
extraceUular  domains of  either the p55 or p75 murine TNF receptor 
(10 #g) emulsified in CFA and boosted three times with the same 
quantity of antigen in IFA at 2-wk intervals. 3 wk after the last 
boost, each animal was given an i.v. injection of 10 #g of the ap- 
propriate antigen diluted in sterile saline. Cultures were screened 
by immunoprecipitation  of radiolabeled soluble receptor protein 
(2 ng/weU) as previously described (33). 
For the anti-p55 fusion, 565/612 growth-positive wells were ob- 
tained, which yielded 20 separate cultures producing p55-specific 
antibody  (3.54%).  The p75 fusion produced 236/408  growth- 
positive wells, and 12 produced p75-specific antibodies (5.08%). 
Antibody-producing hybridomas were cloned by limiting dilution. 
mAbs were purified from clone culture supernatants by use of  Affi- 
Prep Protein A Silica (Bio-Rad Laboratories,  Richmond, CA) chro- 
matography as previously described (29) and HPLC gel filtration. 
All antibody stocks contained <200 pg endotoxin per milligram 
of protein when analyzed by the Limulus amebocyte lysate assay. 
LigandBindinglnhibition.  The ability of anti-p55 and anti-p75 
mAbs to block ligand binding to L929 was determined by use of 
a protocol similar to that described previously (34). 4 million L929 
ceils were preincubated for 1 h at 4~  with serial dilutions ofmAb 
and then incubated with radiolabeled recombinant TNF in a final 
total volume of 200 #1. To monitor binding of TNF to p55, 4 ng 
nSI-labeled human TNF was used in the experiment since human 
TNF binds only to murine p55 TNF receptors (8). To monitor 
binding of TNF to p75 TNF receptors, cells were first incubated 
with 5 #g unlabeled human TNF for 1 h at 4~  to block the p55 
TNF receptor, exposed to mAb, and then incubated with 20 ng 
nSI-labeled murine TNF. The level of nonspecific binding in each 
experiment was determined by adding a 100-fold excess of unla- 
beled human or murine TNF to control wells. Cell-associated  and 
free radioactivity were separated by centrifugation over a phthalate 
oil mixture (34) and the percent inhibition of specific  binding de- 
termined. 
Immunotrrecipitation, SDS-PAGE, and Immunoblotting.  L929  cells 
(2  x  107) were lysed in  1 ml PBS containing  1% Triton X-100 
and protease inhibitors as previously described (35). Samples were 
precleared  by 1-h incubation with 50 #1 protein A-Sepharose slurry 
(Pharmacia Fine Chemicals, Piscataway, NJ) and then incubated 
overnight at 4~  with 20 #g mAb. 50/~1 of protein A-Sepharose 
was added to each sample and incubated an additional 4 h. Beads 
were pelleted by centrifugation and washed three times with I ml 
immunomix (35) and once with I ml PBS. Beads were resuspended 
in 70/A of Laemmli sample buffer (36), boiled 10 min, and cen- 
trifuged. 
Half of each sample was applied to a 12% polyacrylamide gel 
and subjected to SDS-PAGE  according to the method of Laemmli 
by use of a mini-Protean II gel apparatus (Bio-Rad Laboratories) 
(36). Western blot analysis was performed as previously described 
(35). Filters were washed in PBS containing 0.05% Tween-20 and 
incubated 2 h with biotin-conjugated anti-p55 (55R-593) or anti- 
p75 (TR75-54) at 2 #g/ml. After washing, filters were incubated 
15 min with peroxidase-conjugated  streptavidin (1:4,000), washed, 
and developed by use of the enhanced chemiluminescence system 
(ECL; Amersham). 
L929 Cytolytic Assay.  TNF-dependent L929 killing activity was 
quantitated as previously described (29). Briefly,  L929 cell cultures 
(80% confluent) were harvested in EDTA, washed, resuspended 
to 7.5  x  10  s cells/ml in medium, and treated with actinomycin 
D (2/xg/ml final concentration). After 2 h at 37~  100/~1 of the 
cell suspension was mixed with 100/A of serial dilutions of either 
mAb or TNF in 96-well flat-bottom culture plates. In assays in 
which cell-bound mAb was cross-linked, 20/~g of afffinity-purified 
goat anti-hamster  Ig was added per well. After 18 h of culture 
at 37~  viability of the cell cultures was determined by vital dye 
staining with crystal violet as previously described (29). 
Neutralization of TNF Activity.  Neutralization of TNF-depen- 
dent cytolytic activity by mAb was quantitated by use of a modi- 
608  p55 and p75 Recombinant Murine TNF Receptor mAbs fication of the TNF bioassay described above. Different concentra- 
tions of mAb were preincubated with actinomycin D-treated L929 
cells (7.5  x  104/well) for 2 h at 37~  A constant  amount of 
TNF was then added to each well and the cultures incubated an 
additional 18 h at 37~  Cell viability was assessed  by crystal violet 
staining. 
Nitric Oxide Assay.  Nitric oxide induction  in  routine  L929 
fibroblasts by MulFN and TNF was assayed  essentially as described 
previously (37, 38). 
CT6 Proliferation.  TNF-dependent proliferation of the routine 
CT6 cytotoxic T cell line was assayed as previously described (11). 
For inhibition studies, cells were preincubated with mAb for 2 h 
at 37~  before addition of 2 ng/well MuTNF. Cultures were pulsed 
with [3H]thymidine (0.5 /~Ci/well) during the final 4-6 h of a 
24-h culture period and cpm incorporated into DNA determined. 
LPS-Galactosamine-induced  Shock.  Groups of 10 C57B1/6J mice 
were injected intraperitoneally with either pyrogen-free saline or 
mAb (250/~g) 24 h before treatment with a combination of  600 ng 
LPS and 10 mg D-galactosamine (intraperitoneally in 0.5 ml). Sur- 
vival was monitored at 4- to 6-h intervals over a period of 72 h (39). 
Listeria  Infection.  Mice  were pretreated with either saline or mAb 
injected intraperitoneaUy 6 h before i.p. administration  of 3,000 
CFU ofListeria monocytogenes  as described (40). Survival  was moni- 
tored twice daily over a 2-wk period. 
TNF-mediated  Skin Necrosis.  Mice  were pretreated with either 
pyrogen-free saline or mAb (100 #g i.p.),  anesthetized with so- 
dium pentobarbital (80 mg/kg), and the hair removed from the 
back. 24 h later, the animals were injected subcutaneously with 
either saline, MuTNF (3/zg), HuTNF (3 or 30 #g), or a mixture 
of 3/zg TNF and mAb (50/~g) in 0.2 ml. Injections were con- 
tinued on a daily basis. Mice were observed twice daily for the ap- 
pearance of local skin hemorrhage and necrosis. At various times 
after treatment, the mice were bled, killed, and tissue prepared for 
histology according to standard procedures. 
Resuks 
Immunoprecipitation of  Receptor  from Cell Surfaces.  Purified 
mAbs were examined for their ability to specifically precipi- 
tate intact receptor from cell surfaces.  Western blot analysis 
showed that three of the anti-p55 mAbs (55R-593, -176, and 
-170) precipitated a protein of the appropriate molecular mass 
from L929 call lysates (Fig. 1, top). In a separate experiment, 
similar results were obtained with a fourth p55-specific mAb, 
55R-286 (not shown). No p55 was precipitated by any of 
the anti-p75 mAbs (TR75-32,  TR75-45,  or TR75-54) or 
control hamster mAbs  specific for the murine type I  IL-1 
receptor (JAMA-147) or TNF-c~ (TN3-19.12). Conversely, 
the p75 receptor was precipitated only by mAb  generated 
against the murine p75 TNF receptor extracellular domain 
(Fig.  1, bottom). In this case, Western blot analysis revealed 
that the anti-p75 mAb precipitated two components, a major 
component of  70 kD and a minor component of  60 kD. Similar 
patterns were seen with two additional p75-specific mAbs, 
TR75-4 and TR-75-89 (data not shown). No TR75-reactive 
bands were identified after precipitation with either the anti- 
p55 mAb or control IgG. The antigenic specificity of each 
mAb was verified by an ELISA that used immobilized purified 
p55 or p75  extraceUular domain (data not  shown).  These 
Figure 1.  Immunoprecipitation  of  TNF receptors  from  L929  cells  with 
anti-p55 and anti-p75 TNF receptor  mAbs. Murine  L929 lysates  were  in- 
cubated  with 20 ~g of  p55- or p75-specific  mAbs and protein  A-Sepharose. 
Precipitates from 107 cells were separated by SDS-PAGE on 12% poly- 
acrylamide gels under nonreducing  conditions, transferred  to nitrocellu- 
lose, and detected  with 2/~g/ml either biotin-conjugated  55R-593 (top) 
or TP,75-54 (bottom). Western blots were developed  with streptavidin- 
HRP (1:4,000) and the ECL system. 
results thus established that each family of mAb reacted only 
with the class of TNF receptor used for immunization and 
that the antibodies recognized the natural receptor molecules 
derived from whole cells. 
Inhibition of  Ligand Binding.  Radioligand-binding studies 
were performed on routine L929 cells,  which express both 
p55  and  p75  TNF  receptors  to  further  characterize  the 
specificity of each mAb. To monitor effects on the p55 TNF 
receptor, the antibodies were tested for their ability to in- 
hibit binding of radiolabeled HuTNF to murine L929 cells 
since the human ligand binds exclusively to the murine p55 
TNF receptor. Incubation ofL929 with 55R-593, 55R-176, 
or 55R-170 produced a dose-dependent inhibition of  binding 
of 4ng 125I-HuTNF (Fig. 2 A). 50% inhibition of HuTNF 
binding was achieved at mAb doses of 4,  5,  and  1,500  ng, 
respectively.  No inhibition was detected with 55R-286, even 
at mAb doses >75 #g/well. Binding of HuTNF was not in- 
hibited with the 6C8 control hamster IgG (Fig. 2 A) or p75- 
specific mAb  (data not  shown). 
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Inhibition of ligand binding by p55- or p75-specific TNF 
receptor mAbs. (A) L929 cells (4  x  106/well) were incubated with in- 
creasing concentrations of 55K-593, -286, -176, -170, or control hamster 
Ig 6C8 for 1 h at 4~  before addition of 4 ng radioiodinated HuTNF. 
Cell-associated and free radioactivity were separated by centrifugation 
through oil. Maximum binding of lzSI-HuTNF was 15,000 cpm, while 
nonspecific  binding in the presence of 5 #g unlabeled HuTNF was <2%. 
(B) To assess  p75-specific  ligand binding, L929 cells were first incubated 
with saturating concentrations of HuTNF (5/~g) for 1 h at 4~  before 
addition of various doses of TK75-4, -32, -45, -54, and -89 or control 
hamster Ig 6C8. After I h at 4~  20 ng radioiodinated  MuTNF was added 
for an additional hour. Samples were harvested as above  and the percent 
binding inhibition determined. Binding of 20 ng labeled  MuTNF yielded 
5,000 cpm, and nonspecific  binding in the presence of an additional 5 #g 
unlabeled MuTNF was 1.89%. 
To assess the ability of the anti-p75 receptor mAb to in- 
hibit ligand binding, L929 ceils were pretreated with saturating 
concentrations  (5/~g) of unlabeled HuTNF (to block all of 
the p55 receptors), followed by addition of 12SI-murine TNF, 
which thus bound exclusively to the 175 TNF receptor.  Three 
p75-specific  mAbs  inhibited  binding  of 125I-MuTNF  in  a 
dose-dependent manner (Fig. 2 B). 50% inhibition of binding 
of 20 ng radiolabeled MuTNF was achieved with 0.5,  0.9, 
and 1.5 ng of TR75-45, -54, and -32, respectively. No inhi- 
bition was observed with the TR75-4 and TR75-89 mAbs 
or control hamster IgG (6C8). Thus, each family of murine 
TNF  receptor-specific  reagents  contained  both  receptor 
blocking and nonblocking mAbs. 
Effect of p55 and p75 mAbs on In  Vitro Cellular Responses 
to TNE  Fig. 3, A  and B, depict the results of experiments 
to determine the agonist activity of the TNF receptor-specific 
mAb in the in vitro L929 killing assay in the absence of ex- 
ogenous TNF.  Only 55R-593 induced L929 cell lysis in a 
dose-dependent fashion (Fig. 3 A). However, addition of goat 
anti-hamster Ig to cultures pretreated with 55R-170 and -176 
induced L929 lysis, while cross-linking of 55R-286-treated 
cultures or cultures treated with the 6C8 control mAb failed 
to induce cell killing (data not shown). The efficacy of 55K- 
593-induced L929 killing was not affected by antibody cross- 
linking.  None of the anti-p75  mAbs induced cytolytic ac- 
tivity when used alone (Fi. 3 B), in combination,  or when 
cross-linked with anti-hamster  Ig (data not shown). These 
results thus demonstrate that 55R-593 displays TNF agonist 
activity and confirms that L929 cell-killing activity can be 
effected solely through  p55 receptor engagement,  but not 
p75 engagement. 
The antibodies were also tested for their capacity to in- 
hibit TNF-dependent L929 killing.  The p55-specific mAbs 
55R-170 and -176 blocked the lytic activity of 3010g MuTNF 
in a dose-dependent fashion. 50% inhibition of TNF activity 
was obtained with 1,000 and 20 ng of the mAbs, respectively 
(Fig.  3 C), and corresponds to their relative abilities to in- 
hibit ligand-receptor interaction. The p55 agonist mAb 55R- 
593, the nonblocking p55 mAb 55R-286, and control mAb 
failed to inhibit MuTNF-dependent cytolytic activity. When 
the experiments were conducted with HuTNF (which binds 
only to the murine p55 TNF receptor), similar results were 
obtained, except that 55R-170 and -176 were more efficient 
inhibitors  (IDs0  =  35  and 2  ng,  respectively)  (Fig.  3 E). 
Thus,  mAbs 55R.-170 and -176  act as TNF antagonists  in 
the L929 killing assay. When similar experiments were per- 
formed with anti-p75  mAbs, partial inhibition  of MuTNF 
lytic activity (up to •60%)  was noted (Fig. 3 D). However, 
the anti-p75  mAbs,  even at doses of 30 #g/well,  failed  to 
inhibit L cell killing mediated by HuTNF (Fig. 3 F). An iden- 
tical pattern  of results was obtained when these two mAb 
families were tested for their ability to induce or inhibit TNF- 
mediated nitric  oxide production  (data not  shown). 
To examine whether the anti-p75 mAbs affected biologic 
responses mediated solely by the p75 TNF receptor, we used 
an assay that  monitors  murine  TNF-induced  proliferation 
of the  murine  CT6  cytotoxic  T  cell  line.  This  cell  line 
proliferates  in response to polyvalent p75-specific antisera, but 
not p55-specific antisera (11). While none of the p75-specific 
mAbs elicited a proliferative response alone, all of the p75- 
specific mAbs induced significant  CT6 expansion when cross- 
linked with goat anti-hamster  Ig (data not shown).  None 
of the p55-specific mAbs, either alone or after cross-linking, 
induced proliferation of CT6. These data thus confirm that 
clustering of the p75 TNF receptor is sufficient to induce 
a proliferative response in these cells. In contrast, TR75-45, 
-54, and -32 inhibited CT6 proliferative responses induced 
by 2 ng MuTNF in a dose-dependent manner (Fig. 4 B). The 
IDs0 values for each mAb (2, 5, and 22 ng, respectively)  cor- 
related with the ability of each mAb to block ligand-receptor 
interaction.  TR75-4 and -89 did not display functional in- 
hibitory activity. Antibodies reactive with p55 TNF receptor 
had no significant inhibitory effect on TNF-dependent CT6 
proliferation  (Fig.  4 A). 
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Figure 3.  Agonist/antagonist activity of TNF receptor 
mAbs for L929 killing. Various dilutions of anti-p55 (A, 
C, and E), anti-p75 (B, D, and F) or control Ig 6C8 were 
preincubated with actinomycin D-treated L929 cells for 2 h 
at 37~  before addition  of either  medium (A and B) or 
30 pg/well MuTNF (C and E) or 700 pg/well HuTNF (D 
and F). Monolayer viability was assessed after 18 h by vital 
dye uptake. Untreated control monolayers exhibited an ab- 
sorbance at 540 nm of 1.2 (A and B) or 1.5 (C-F). Incuba- 
tion with murine or human TNF resulted in readings of 
0.32 and 0.22,  respectively. 
Effects of  p55 and p75 mAb In Vim  Pharmacokinetic studies 
performed on each antibody in naive BALB/c mice established 
that all mAbs displayed serum half-lives of ~2 d (data not 
shown). The half-life of each antibody remained unchanged 
in mice that received  four mAb injections over a 16-wk period. 
Thus the hamster anti-TNF receptor mAbs were not immuno- 
genic in mice. 
To examine the efficacy of the receptor-specific mAbs in 
vivo, we initially used two experimental systems (LPS/galac- 
tosamine-mediated lethal shock and resistance to infection 
by L. monocytogenes),  which, based on experiments with p55- 
deficient mice, are known to be obligatorily  dependent on 
p55 TNF receptor engagement (21, 22). Animals pretreated 
with either saline or control hamster IgG succumbed to the 
lethal combination of LPS and galactosamine within 24 h 
(Fig. 5 A). Pretreatment of mice with 250/kg TN3-19.12 
(a neutralizing hamster mAb specific  for murine TNF-o  0 com- 
pletely protected mice from lethal shock. Mice pretreated with 
the antagonistic 55R-170 mAb were also protected from le- 
thal shock. Similar results were obtained by use of the other 
p55 antagonist mAb 55R-176 (data not shown). In separate 
dose-response experiments, 40 #g of 55R-170 was sufficient 
to provide complete protection (data not shown).  In con- 
trast,  the antagonistic anti-p75 TNF receptor mAb TR75- 
54 was not protective at  any dose. 
In the Listeria infection model, mice treated either with 
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Fig,r~ 4.  Anti-p75  inhibition  of TNF-mediated  CT6 proliferation.  CT6 
cells (5  ￿  104) were incubated with anti-p55 (A), anti-p75 (B), or con- 
trol hamster  mAb 6C8 for 2 h at 37~  before addition  of 2 ng MuTNF. 
Cultures were pulsed after 20 h with [3H]thymidine  for an additional 
4-6 h and the percent of control response determined. Cultures stimu- 
lated  with 2 ng MuTNF  alone  yielded  12,300 cpm with background  counts 
<3,500. 
Figure 5.  In vivo  activity  of  TNF receptor-specific  mAbs. (A) LPS/galac- 
tosamine-mediated  lethal  shock.  Groups  of 10 C57B1/6 mice  were  treated 
with saline or 250 #g mAb 24 h before challenge  with a combination 
of LPS (600 rig) and D-galactosamine  (10 mg). Survival  was monitored 
over a 48-h period. (B) Listeria  infection.  Groups of 5 C3H/HeJ  mice  were 
injected  intraperitoneally  with 250/~g antibody  6 h before  infection  with 
3,000 live  Listeria organisms. Survival  was monitored  twice  daily  over a 
10-d period. Depicted is one of six representative experiments. 
saline or irrelevant hamster mAb mounted a protective anti- 
Listeria response and survived infection with 3,000 live Listeria 
organisms (Fig. 5 B). Mice treated with anti-TNF became 
susceptible to lethal infection and died. Animals treated with 
the antagonist p55-specific mAb (55R-170)  failed to generate 
an anti-Listeria response and succumbed to the infection. As 
little as 25/~g of 551%-170 was sufficient to render all the 
animals susceptible  to infection (data not shown).  In con- 
trast, TR75-54 did not inhibit the development of an anti- 
Listeria response in mice. Subsequent testing of T1%75-32, 
-45,  and -54 at doses of 250 and 500/zg per mouse showed 
that none of the p75-specific mAbs affected development of 
anti-Listeria  responses  (not shown).  Thus, in both in vivo 
models, anti-p55-treated mice responded similarly to mice 
lacking the p55 TNF receptor.  Moreover, antibody blockade 
of p75  was without functional consequences. 
p75  TNF Receptor Engagement  Is Required for MuTNF- 
mediated Skin Necrosis.  Whereas the aforementioned studies 
confirmed the physiologic requirement of  p55 TNF receptors 
in promoting protective and immunopathologic responses to 
bacteria and their products in vivo, no information was ob- 
tained that helped define the physiologic role of p75  TNF 
receptors. Insights into p75's biologic role in vivo were gained 
from experiments being conducted to explore TNF's  im- 
munosuppressive activities.  In these studies, daily subcuta- 
neous injections of either murine or human TNF into mice 
led to a state of immunosuppression that blocked xenograft 
rejection (41) and inhibited T cell priming to the soluble pro- 
tein antigen, hen egg lysozyme  (Sheehan, K., and R. Schreiber, 
unpublished observations).  During the course of these  ex- 
periments, we observed that subcutaneous injection of 3/zg 
MuTNF produced severe hemorrhage in the skin and subse- 
quent necrosis at the injection site (Fig. 6 B), while s.c. injec- 
tion of 3 or 30 #g HuTNF did not (Fig.  6 C).  In CBA/J 
mice, the lesion induced with MuTNF was observed  after 
three to five daily injections. The lesion initially presented 
as a reddening of the skin, followed by intradermal hemor- 
rhage and skin necrosis. Histologically, the full-thickness skin 
and subcutaneous sections of the saline- and HuTNF-treated 
mice disclosed an absence of microscopic abnormalities (Fig. 
7, A and C) to correspond with the unremarkable gross fea- 
tures depicted in Fig. 6, A and C. In contrast, early epidermal 
necrosis,  transdermal neutrophilia and hemorrhage, subcu- 
taneous hemorrhage, and recent thrombi were present in the 
MuTNF-treated mice (Fig.  7 B, inset). This result thus sug- 
gested that the p75 TNF receptor was involved in this process. 
612  p55 and p75 Recombinant  Murine TNF Receptor mAbs Figure  6.  Prevention  of  MuTNF-induced  skin 
necrosis by anti-p55 and anti-p75 TNF recep- 
tor-specific mAbs. Mice  were  pretreated on day 
-1 with either saline or 100 Izg of antibody  in- 
traperitoneally  and injected  daily  with 3/~g  TNF 
alone or combined  with 50/lg mAb subcutane- 
ously over a period of 7 d. (A) Saline alone; (B) 
MuTNF only; (C) HuTNF  only; (D) MuTNF + 
6C8 control IgG; (E) MuTNF + 55R-170; and 
(F) MuTNF +  TP,75-54. 
To  further  confirm  the  roles  of the p55  and  p75  TNF 
receptors in this process, mice were treated with MuTNF ei- 
ther  alone or in combination with  control or antagonistic 
p55- or p75-specific mAbs. None of the mAbs individually 
or collectively induced  the skin necrosis reaction  (data not 
shown). Pretreatment  of mice with antagonistic p75 mAbs 
(TR75-32  or -54) completely blocked the development  of 
the skin reaction (Fig. 6 F) as well as any histologic changes 
(Fig.  7 F).  Similar results were obtained by use of the p55- 
specific antagonistic mAb 55R-170 (Figs. 6 E and 7 E). Con- 
trol hamster Ig was without effect, resulting in a composite 
of microscopic changes virtually identical  to those in mice 
treated with MuTNF alone (Fig. 7 B) with epidermal necrosis, 
hemorrhage,  neutrophilia,  and thrombosis (Figs.  6 D  and 7 
D). These results thus demonstrate,  for the first time, an in 
vivo role for the p75 TNF receptor and suggest that p75 en- 
gagement may be directly involved in certain types of acute 
inflammatory  and hemorrhagic  reactions. 
Discussion 
The  studies presented  here document  the production  of 
hamster mAbs specific  for the extracellular domains of the 
p55 and p75 murine TNF receptors.  These reagents repre- 
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sent the first murine TNF receptor-specific mAbs to be gener- 
ated. Each member of the anti-p55 or anti-p75 mAb family 
displayed strict specificity for the receptor form used for im- 
munization.  Within  the anti-p55  family, 55R-286 did not 
interfere with p55-TNF  interaction,  while 55R-170,  -176, 
and -593 blocked the ability of p55 to bind ligand in a dose- 
dependent manner. Three p75-specific mAbs (TR75-32, -45, 
and -54) were identified that blocked ligand-receptor inter- 
action,  while two others  (TR75-4  and  -89)  did not. 
Functionally, the antibodies could be distinguished by their 
effects in well-defined in vitro TNF bioassays.  By use of the 
L cell-killing  assay, the anti-p55 mAb family was found to 
contain  one mAb (55R-593)  that  acted as a TNF  agonist, 
two (55R-170 and -176) that  acted as antagonists,  and one 
(55R-286)  that  did not  affect  TNF's  actions on p55.  The 
production  of an  agonistic anti-routine  p55 TNF  receptor 
mAb is notable because its functional activity makes it unique 
among anti-p55 mAbs. Although it has been shown that sig- 
naling  through  the p55 TNF receptor is initiated by oligo- 
merization of surface receptors using either polyvalent anti- 
p55 sera (11, 42) or homotrimeric  ligand  (43),  the activity 
of the 55R-593 mAb presented in this report suggests that 
dimerization  of the p55 TNF receptor may be sufficient to Figure  7.  Histologic examination of TNF-mediated 
skin necrosis. Mice were treated as above with 100/zg 
antibody  intraperitoneally  on day  -1 and 3 #g TNF 
alone or in combination with 50/~g antibody  sub- 
cutaneously daily. After 4 d, mice were killed and tissue 
processed and stained with hematoxalin and eosin. In 
vivo treatments  are as follows: (tt)  saline only;  (B) 
MuTNF alone; (C) HuTNF alone; (D) MuTNF  + 6C8 
control  IgG;  (E)  MuTNF  +  55R-170;  and  (F) 
MuTNF  +  TR75-32.  x200. induce a biologic response in these cells. Importantly, the 
antagonistic p55-specific mAb could be converted into agonists 
after cross-linking. In fact, in early experiments, small amounts 
of high molecular weight mAb aggregates present  in the 
purified antibody preparations led to an agonist action of 55R- 
170 and -176. Addition of a gel filtration  step to the mAb 
purification procedure separated the high molecular mass ag- 
gregates that displayed potent agonist activity from the bulk 
of the monomeric mAbs that displayed antagonistic activity. 
When 55R-593 was subjected to the same gel filtration pro- 
cedure, the agonist activity coeluted with monomeric anti- 
body, con- firming that 55R-593 acted as an agonist in its 
native form. Thus, these results not only document the func- 
tional activity of the p55-specific mAbs, but also confirm the 
concept that engagement of  p55 is both necessary  and suf~cient 
to induce killing of L929 cells. 
The same assays were used to show that the anti-p75 mAb 
family contained three members that acted as p75 antago- 
nists (TR75-32,  -45, and -54) and two that were unable by 
themselves  to affect  TNF-dependent biologic responses in cells 
(TR75-4 and -89). By use of the CT6 proliferation  assay, 
TR75-32,  -45, and -54 were found to inhibit MuTNF-driven 
proliferative responses in a dose-dependent  manner,  while 
TR75-4 and -89 did not. These mAbs represent  the only 
reagents currently available that display antagonist  activity 
for the murine p75 TNF receptor and thus document that 
engagement of p75 is both necessary and su~cient to induce 
proliferative responses in CT6 cells. 
The p75 antagonist mAbs also partially inhibited MuTNF- 
dependent L  cell  killing.  Inhibition  was  never  complete 
(40-60%) and could be overcome if higher concentrations 
of murine TNF were used. Moreover, none of the anti-p75 
reagents effected L cell killing when cross-linked in the ab- 
sence of TNF. These results thus best support the model where 
p75 plays an accessory role in the killing process. The precise 
role of p75 in mediating L cell killing remains controversial. 
Heller et al. (23, 24) proposed that p75 can directly signal 
for cytotoxicity, while Tartaglia et al. (12, 30) proposed that 
p75  facilitates ligand uptake  onto p55  and that p55 is the 
sole TNF receptor responsible for initiating the L cell-killing 
response. Recently, the latter "ligand-passing model" has been 
supported by the results of structural analyses  of the two TNF 
receptors' intracellular domains. The p55 intracellular domain 
contains a "death domain" similar to that found in the intra- 
cellular domain of the Fas antigen that is important in effecting 
cell killing  (44), while the p75  TNF  receptor does  not. 
Moreover, additional  support  for a ligand-passing function 
has been derived from the characterization of mice with selec- 
tive genetic deficiencies  of either the p55 (21, 22) or p75 (44a) 
TNF receptors. 
To initially examine the potential  usefulness of the anti- 
p55 and -p75 mAbs in vivo, we used two well-characterized 
murine models (39, 45) that are known to be unequivocally 
dependent on endogenous TNF production. As little as 25 
or 40 #g of antagonistic anti-p55 inhibited development of 
a protective immune response to L.  monocytogenes in naive 
mice and protected normal mice from the lethal effects of 
LPS/galactosamine, respectively. In contrast,  up to 500/zg 
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quantities of antagonistic p75 TNF receptor-specific mAbs 
were without biologic  effects. Importantly,  these  results 
recapitulate the observations made by others using mice lacking 
p55 (21, 22) or p75 (44a) and thereby validate the in vivo 
effects of our anti-p55  and anti-p75  mAbs. 
The characterization of the specificities and functional ac- 
tivities of the murine TNF receptor-specific mAbs was based 
on the known structure and function of the two receptors. 
Whereas  definitive experiments  have now been performed 
that define at least some of the physiologic roles of the p55 
TNF receptor as they occur in vivo, little information is avail- 
able concerning the physiologic function of the p75 TNF 
receptor. The availability of antagonistic mAbs specific for 
the murine p75 TNF receptor has permitted us to identify 
a heretofore unrecognized role of this protein in promoting 
inflammatory  responses. Previous studies by others (46) have 
indicated that TNF plays an important role in the develop- 
ment of naturally occurring cutaneous diseases. Moreover, 
subcutaneous injection of highly purified recombinant TNF 
into the skin of normal mice and rabbits  has been shown 
by some groups to induce intradermal hemorrhage and skin 
necrosis (47, 48). In studies in which human TNF was ad- 
ministered to experimental animals, the development of the 
cutaneous inflammatory response was found to require the 
additional presence of  bacterial products (49), whereas repeti- 
tive subcutaneous administration  of LPS-free murine TNF 
to mice led to generation of clear necrotic skin lesions (46, 48). 
Based on the recognized differential species specificity dis- 
played by the p55 and p75 routine TNF receptors for human 
versus murine TNF, the previous discrepant results suggested 
that both p55 and p75 TNF receptors might be involved in 
the process. In this report, we show that whereas repeated 
injections of MuTNF induced frank intradermal hemorrhage 
and severe  skin necrosis, repeated injections of up to 10 times 
larger quantities  of human TNF were without effect. This 
result suggested that p75 was involved in the inflammatory 
skin reaction. This hypothesis was supported by our obser- 
vation that TNF-induced skin necrosis could be inhibited by 
administration of antagonistic p75-specific mAbs. Moreover, 
since skin necrosis was also inhibited by blocking p55-specific 
mAbs, the ultimate development of in vivo inflammatory re- 
sponses in the skin must be due to engagement of  both TNF 
receptor forms. 
At this time, the identity of the cells whose function is 
regulated by the p75  and p55 TNF receptors remains un- 
known. It is also unclear whether the dual requirement for 
p55 and p75 in this process involves a single cell population 
that is  stimulated  by engagement of both types of TNF 
receptors or multiple cell populations that are specifically  in- 
duced to perform their function through engagement of one 
or the other TNF receptors. The gross and histologic findings 
in this study, in particular  the presence of neutrophilia,  in- 
tense hemorrhage, and thrombosis,  would suggest that en- 
dothelial cells and neutrophils may be important cellular par- 
ticipants in this model.  It is noteworthy that, based on in 
vitro experiments, others (50) have suggested that p75 may 
be important in effecting biologic response induction in en- 
dothelial cells. Studies are currently underway in the labora- tory to define the precise physiologic roles of p55 and p75 
in promoting inflammatory reactions. 
Thus, we have documented the production and antigen- 
binding characteristics  of two novel families of hamster mAbs 
specific for the murine p55 and p75 TNF receptors. The ability 
of these mAbs to function in vitro and in vivo coupled with 
their lack of immunogenicity in vivo provides the opportu- 
nity to modulate TNF-mediated responses in a receptor-specific 
fashion. The availability of these monoclonal murine TNF 
receptor-specific reagents will thus facilitate investigations 
aimed at defining the molecular basis for TNF's pleiotropic 
actions and the physiologic roles of the two TNF receptors 
in vivo. 
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